A part of Watch Media

MedWatchWednesday4 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchWednesday4 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Pharma & biotech

Ascendis has launched weekly growth hormone in first European market

The biotech company is also looking for country managers for a number of European locations.
Ascendis' headquarters in Hellerup. | Photo: Ascendis Pharma / Pr
Ascendis' headquarters in Hellerup. | Photo: Ascendis Pharma / Pr
by MIKKEL AABENHUS HEMMINGSEN

As expected, the biotech company Ascendis Pharma has now launched the weekly growth hormone Skytrofa in Germany.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Related articles:

  • Photo: Kevin Grønnemann

    Ascendis to launch weekly growth hormone i first European country this september

    For subscribers

  • Photo: Kevin Grønnemann

    Ascendis gets USD 150m in cash from selling synthetic royalty

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Photo: Tom Little
Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom

The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.
  • Bank downplays importance of patent dispute and FDA notice to Novo Nordisk
  • Jefferies on Novo Nordisk: Little risk of semaglutide patent dispute - but could raise concerns

For subscribers



Foto: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

For subscribers



Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers


Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers


Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug


Foto: Yuriko Nakao/Reuters/Ritzau Scanpix
Medtech

Olympus appoints new chief medical officer

For subscribers


  • Foto: Alexander Heinl/AP/Ritzau Scanpix

    Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

    Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

    For subscribers


  • Vaccine breakthrough behind mRNA shots wins Nobel Prize

    The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.

    For subscribers


  • Foto: Ws Audiology / Pr

    WS Audiology hires new chief technology officer from car manufacturer

    He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.

    For subscribers


  • Foto: Tom Little

    Novo Nordisk files lawsuit against US authorities ahead of price negotiation

    The litigation is the latest in a long line of industry lawsuits related to price negotiations.

    For subscribers


  • Foto: Mike Segar

    FDA rejects atopic dermatitis drug lebrikizumab

    Eli Lilly had expected a launch this year.

    For subscribers


  • The FDA has updated the package label of Novo Nordisk's diabetes drug, Ozempic, with a warning about intestinal blockage disorder as a possible side effect. | Foto: Tom Little/Reuters/Ritzau Scanpix

    FDA updates Novo Nordisk's Ozempic drug label with side effect alert

    The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.

    For subscribers


Further reading

Scott Thomas Smith, CFO of Ascendis Pharma. | Foto: Ascendis Pharma / Pr
Pharma & biotech

Ascendis CFO sells shares worth DKK millions

The deal happens just over a week after Ascendis began the rollout of its weekly growth hormone, Skytrofa, in Europe.

For subscribers



Foto: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers



Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

The contract manufacturer has hired a chief people officer with immediate effect.

For subscribers


Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.


Photo: Kevin Grønnemann
Pharma & biotech

Ascendis to launch weekly growth hormone i first European country this september

The launch comes more than a year and a half after approval.

For subscribers



Photo: Kevin Grønnemann
Pharma & biotech

Ascendis gets USD 150m in cash from selling synthetic royalty

Starting January 2025, Royalty Pharma will receive a share of the revenue from the sale of weekly growth hormone Skytrofa in the US. 

For subscribers


Jobs

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Project Director, HR & ESG

  • VP of Software Development, Perfusion Tech

  • Scientist - Bioanalysis, Biologics

  • Senior QA Specialists (GMP or GCP)

  • Senior Analytical Scientists

  • Senior Legal Councel

  • Clinical Trial Manager

  • QA/RA Manager

  • Director, Head of Antibody Technology

  • Audit & Supplier Manager

  • Qualified Person to AJ Vaccines

  • Clinical Supply Manager

  • Global Medical Manager

  • Supply Value Stream (SVS) Project Manager

See all jobs

Latest news

  • Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom –
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
  • Fujifilm expands management with former Leo executive –
  • Snack maker keeps an eye on Novo Nordisk's obesity drug –
  • FDA approves Novo Nordisk drug to treat rare condition –
  • FDA updates Novo Nordisk's Ozempic drug label with side effect alert –
  • FDA rejects atopic dermatitis drug lebrikizumab –
  • FDA to support new orphan drugs through pilot program –
See all

Jobs

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Project Director, HR & ESG

  • VP of Software Development, Perfusion Tech

  • Scientist - Bioanalysis, Biologics

  • Senior QA Specialists (GMP or GCP)

  • Senior Analytical Scientists

  • Senior Legal Councel

  • Clinical Trial Manager

  • QA/RA Manager

  • Director, Head of Antibody Technology

  • Audit & Supplier Manager

  • Qualified Person to AJ Vaccines

  • Clinical Supply Manager

  • Global Medical Manager

  • Supply Value Stream (SVS) Project Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved